[go: up one dir, main page]

PE20100265A1 - Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion - Google Patents

Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion

Info

Publication number
PE20100265A1
PE20100265A1 PE2010000095A PE2010000095A PE20100265A1 PE 20100265 A1 PE20100265 A1 PE 20100265A1 PE 2010000095 A PE2010000095 A PE 2010000095A PE 2010000095 A PE2010000095 A PE 2010000095A PE 20100265 A1 PE20100265 A1 PE 20100265A1
Authority
PE
Peru
Prior art keywords
composition
weight
amount
preparation
levetiracetam
Prior art date
Application number
PE2010000095A
Other languages
English (en)
Inventor
Michel Deleers
Jean-Benoît Hubert
Original Assignee
Glaxo Smithkline Trading Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100265(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Smithkline Trading Services Ltd filed Critical Glaxo Smithkline Trading Services Ltd
Publication of PE20100265A1 publication Critical patent/PE20100265A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) LEVETIRACETAM COMO INGREDIENTE ACTIVO EN UNA CANTIDAD DE 80% A 95% EN PESO DE LA COMPOSICION; B) CROSCARMELOSA SODICA EN UNA CANTIDAD DE 2.0% A 9.0% EN PESO DE LA COMPOSICION; C) AGENTE SILICE COLOIDAL ANHIDRA EN UNA CANTIDAD DE HASTA 3.0% EN PESO DE LA COMPOSICION; D) POLIETILENGLICOL 6000 EN UNA CANTIDAD DE 0.5% A 6.0% EN PESO DE LA COMPOSICION; E) ESTEARATO DE MAGNESIO EN UNA CANTIDAD DE HASTA 1.0% EN PESO DE LA COMPOSICION; Y F) UN AGENTE DE RECUBRIMIENTO TAL COMO UNA DISPERSION ACUOSA DE HIDROXIPROPILMETILCELULOSA O POLI(ALCOHOL VINILICO). SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE DICHA COMPOSICION EN DONDE LEVETIRACETAM ES UTIL EN EL TRATAMIENTO DE EPILEPSIA
PE2010000095A 2005-07-26 2006-07-24 Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion PE20100265A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05016189 2005-07-26
EP05016945 2005-08-04

Publications (1)

Publication Number Publication Date
PE20100265A1 true PE20100265A1 (es) 2010-04-21

Family

ID=36888840

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000890A PE20070216A1 (es) 2005-07-26 2006-07-24 Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
PE2010000095A PE20100265A1 (es) 2005-07-26 2006-07-24 Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000890A PE20070216A1 (es) 2005-07-26 2006-07-24 Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion

Country Status (25)

Country Link
US (1) US8802142B2 (es)
EP (1) EP1909764B1 (es)
JP (2) JP5183470B2 (es)
KR (1) KR20080030546A (es)
CN (1) CN101068534B (es)
AR (1) AR054581A1 (es)
AU (1) AU2006274263B2 (es)
BR (1) BRPI0606121A2 (es)
CA (1) CA2581831C (es)
CY (1) CY1115825T1 (es)
DK (1) DK1909764T3 (es)
EA (1) EA014961B1 (es)
ES (1) ES2524771T3 (es)
HR (1) HRP20141185T1 (es)
IL (1) IL182375A0 (es)
MX (1) MX2007004294A (es)
NO (1) NO20071667L (es)
NZ (1) NZ554157A (es)
PE (2) PE20070216A1 (es)
PL (1) PL1909764T3 (es)
PT (1) PT1909764E (es)
RS (1) RS53690B1 (es)
SI (1) SI1909764T1 (es)
TW (1) TW200738280A (es)
WO (1) WO2007012439A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080029A1 (en) 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
US20070172521A1 (en) * 2006-01-24 2007-07-26 Julia Hrakovsky Levetiracetam formulations and methods for their manufacture
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN101422442A (zh) * 2008-12-09 2009-05-06 沈阳药科大学 左乙拉西坦渗透泵控释片及其制备方法
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
MX2011007267A (es) * 2009-01-29 2011-08-15 Ucb Pharma Sa Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
CA2765734C (en) 2009-06-26 2016-12-13 Taris Biomedical, Inc. Implantable drug delivery devices and methods of making the same
CN102038657B (zh) * 2009-10-10 2015-04-15 浙江华海药业股份有限公司 左乙拉西坦片及其制备方法
WO2011121593A1 (en) * 2010-03-29 2011-10-06 Hetero Research Foundation Stable pharmaceutical composition of imatinib
TR201011148A1 (tr) 2010-12-30 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Levetirasetam farmasötik bileşimleri.
JP2014505108A (ja) * 2011-02-09 2014-02-27 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
CN102188420B (zh) * 2011-03-25 2013-04-10 华润赛科药业有限责任公司 一种左乙拉西坦的药物组合物及其制备方法
CN102895214B (zh) * 2012-10-25 2014-03-26 杭州朱养心药业有限公司 左乙拉西坦片剂的固体药物组合物
CN102871981B (zh) * 2012-10-25 2013-11-13 杭州朱养心药业有限公司 包含左乙拉西坦的片剂药物组合物
CN103127175B (zh) * 2013-02-22 2014-01-22 张晓光 一种抗癫痫药物及其制备方法
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP3431141B1 (en) 2013-03-15 2021-12-08 Aprecia Pharmaceuticals LLC Three-dimensional printing method
EP3074004A2 (en) * 2013-11-29 2016-10-05 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
CN104666263B (zh) * 2015-02-09 2017-07-11 海南华益泰康药业有限公司 一种含有左乙拉西坦的片剂及其制备方法
JP6899043B2 (ja) * 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド レベチラセタムの持続放出性医薬組成物
JP6630229B2 (ja) * 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN107913258A (zh) * 2016-10-09 2018-04-17 北京阜康仁生物制药科技有限公司 一种左乙拉西坦缓释片及其制备方法
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7264711B2 (ja) * 2019-04-26 2023-04-25 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法
JP7575217B2 (ja) * 2019-08-09 2024-10-29 日本ジェネリック株式会社 レベチラセタムを含む錠剤
CN117838643A (zh) * 2023-12-29 2024-04-09 山东力诺制药有限公司 一种吡拉西坦片及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPH07503859A (ja) * 1992-10-09 1995-04-27 ヴァイシス・インコーポレーテッド 挿入エレメントおよび増幅可能な核酸
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
DE60034815T2 (de) 1999-12-01 2008-01-31 Ucb S.A. Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
EP1392290B1 (en) 2001-03-22 2005-05-18 Ucb, S.A. Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases
AU2003242538A1 (en) 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
WO2004051222A2 (en) 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
CA2515090A1 (en) * 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd Process for producing levetiracetam
CN102000336A (zh) * 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
WO2006080029A1 (en) 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam

Also Published As

Publication number Publication date
MX2007004294A (es) 2008-03-11
KR20080030546A (ko) 2008-04-04
CN101068534A (zh) 2007-11-07
JP5183470B2 (ja) 2013-04-17
EA014961B1 (ru) 2011-04-29
JP2009502835A (ja) 2009-01-29
US20080269316A1 (en) 2008-10-30
EP1909764A1 (en) 2008-04-16
AR054581A1 (es) 2007-06-27
DK1909764T3 (da) 2014-12-15
WO2007012439A1 (en) 2007-02-01
PL1909764T3 (pl) 2015-03-31
AU2006274263A1 (en) 2007-02-01
CA2581831A1 (en) 2007-02-01
BRPI0606121A2 (pt) 2009-10-06
PE20070216A1 (es) 2007-03-27
HRP20141185T1 (hr) 2015-01-30
JP2013018786A (ja) 2013-01-31
US8802142B2 (en) 2014-08-12
CY1115825T1 (el) 2017-01-25
CA2581831C (en) 2013-11-12
AU2006274263B2 (en) 2011-01-27
TW200738280A (en) 2007-10-16
ES2524771T3 (es) 2014-12-12
SI1909764T1 (sl) 2015-01-30
EA200700566A1 (ru) 2008-08-29
NO20071667L (no) 2007-04-26
RS53690B1 (sr) 2015-04-30
EP1909764B1 (en) 2014-09-10
NZ554157A (en) 2010-12-24
HK1109071A1 (en) 2008-05-30
CN101068534B (zh) 2011-09-07
PT1909764E (pt) 2014-12-18
IL182375A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
MX2009013810A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos.
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
UA93496C2 (uk) Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу
BR112016002915A2 (pt) formulação agroquímica pulverizável, formulação concentrada, uso de um éster graxo de um poliol c3 a c8, ou oligômero do mesmo, e, métodos para reduzir o desvio de pulverização e para tratamento de vegetação para controlar pestes e/ou fornecer nutrientes
MX340701B (es) Alquil lactil - lactatos y procesos para fabricar los mismos.
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
CL2011002648A1 (es) Composicion topica que comprende un compuesto derivado de 1,2,4-tiadiazol o tiourea, un agente modificador de la viscosidad, un conservante y agua; estuche para la composicion; metodo para preparar la composicion; y uso para tratar una enfermedad o trastorno dermatologico mediado por un receptor de melanocortina tal como acne.
BRPI0907970A8 (pt) composição para tratamento dos cabelos ou pelos e método para aumentar o diâmetro dos cabelos ou pelos
PE20091313A1 (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
MX2018005786A (es) Formulaciones novedosas.
AR075063A1 (es) Composiciones que comprenden agentes tensoactivos no ionicos y zwiterionicos
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
EP2515912A4 (en) PHARMACEUTICAL COMPOSITION WITH VITAMIN D ANALOGON AND COLOSTERS-TENSID MIXTURE
WO2016116403A8 (en) Polyurethaneurea solutions for compositions with active ingredients or fragrances
CL2012000611A1 (es) Compuesto 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2- trifluoro-etoxi)-nicotinamida, util como agente que aumenta el colesterol hdl; proceso de obtencion del compuesto; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la aterosclerosis, dislipidemia, enfermedades cardiovasculares, entre otras.
BRPI0518781A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto

Legal Events

Date Code Title Description
FD Application declared void or lapsed